08:01 AM EDT, 10/27/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Monday it has paused patient dosing and screening for its two phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, respectively, after a patient was reported with Grade 4 liver transaminases and increased total bilirubin after dosage with the drug.

The patient was hospitalized and is receiving medical intervention, the company said.

Intellia said it is consulting with experts and is considering potential risk mitigation strategies, as well as engaging with regulatory authorities with the aim of resuming enrollment as soon as appropriate.